Influence of PI3K/AKT pathway on imatinib mesylate treatment outcome in chronic myeloid leukemia patients

被引：0
|
作者：
Banapuram, Swathi [1 ]
Gorre, Manjula [1 ]
Digumarti, Raghunadha Rao [2 ]
Satti, Vishnupriya [1 ]
Palle, Komaraiah [3 ]
Annamaneni, Sandhya [3 ,4 ]
机构：
[1] Osmania Univ, Hyderabad, Telangana, India
[2] Homi Bhabha Canc Hosp & Res Ctr, Visakhapatnam, Andhra Pradesh, India
[3] Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79430 USA
[4] Osmania Univ, Dept Genet, Hyderabad, Telangana, India
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-4682
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4682
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Long noncoding RNA HULC promotes cell proliferation by regulating PI3K/AKT signaling pathway in chronic myeloid leukemia
    Lu, Yinghao
    Li, Yan
    Chai, Xiao
    Kang, Qian
    Zhao, Peng
    Xiong, Jie
    Wang, Jishi
    GENE, 2017, 607 : 41 - 46
  • [32] IMATINIB MESYLATE INDUCED HEPATOTOXICITY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)
    Milosevic, V.
    Bogdanovic, A.
    Djordjevic, V.
    Fekete, M. Dencic
    Mihaljevic, B.
    Gotic, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 545 - 546
  • [33] Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate
    Arora, B
    Kumar, L
    Sharma, A
    Wadhwa, J
    Kochupillai, V
    ANNALS OF ONCOLOGY, 2004, 15 (02) : 358 - 359
  • [34] Administration of imatinib mesylate in patients with chronic myeloid leukemia with short bowel
    Yamazaki, Rie
    Aisa, Yoshinobu
    Mori, Takehiko
    Iketani, Osamu
    Ikeda, Yasuo
    Okamoto, Shinichiro
    LEUKEMIA & LYMPHOMA, 2009, 50 (04) : 670 - 672
  • [35] Cytogenetic responses in chronic myeloid leukemia patients treated with imatinib mesylate
    Babameto-Laku, A.
    Mokin, V.
    Cikuli, M.
    Xhumari, P.
    CHROMOSOME RESEARCH, 2005, 13 : 158 - 158
  • [36] Imatinib mesylate, a new drug for chronic myeloid leukemia in pediatric patients
    Thavaraj, Vasantha
    Seth, Rachna
    WORLD JOURNAL OF PEDIATRICS, 2007, 3 (02) : 110 - 114
  • [37] Nutritional Status of Patients with Chronic Myeloid Leukemia Treated with Imatinib Mesylate
    Jose Castillo-Martinez, Maria
    Juventina Tuna-Aguilar, Elena
    del Pilar Milke-Garcia, Maria
    Camacho Zamora, Anais
    Villegas Cervantes, Viviana
    Castillo-Martinez, Lilia
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2022, 74 (09): : 3211 - 3216
  • [38] Dual PI3K/Akt/mTOR Pathway Inhibitor Potentiate Cytarabine Cytotoxicity For Acute Myeloid Leukemia
    Kim, Eun Kyung
    Kang, Hyoung Jin
    Kim, Hyung Joon
    Lee, Ji Won
    Kim, Hyery
    Park, Kyung Duk
    Shin, Hee Young
    Ahn, Hyo Seop
    BLOOD, 2013, 122 (21)
  • [39] IMATINIB MESYLATE IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
    Ionita, H.
    Ionita, I.
    Cheveresan, M.
    Iordache, M.
    Cheveresan, L.
    Ionita, M.
    Borzak, G.
    Ionita, C. O.
    Pascalau, A.
    Calamar, D.
    Oros, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 548 - 548
  • [40] FIRST LINE TREATMENT OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH THE GENERIC FORMULATIONS OF IMATINIB MESYLATE
    Eskazan, A. E.
    Baslar, Z.
    Ayer, M.
    Kantarcioglu, B.
    Arica, D.
    Demirel, N.
    Aydin, D.
    Yalniz, F. F.
    Elverdi, T.
    Salihoglu, A.
    Ar, M. C.
    Aydin, S. Ongoren
    Aydin, Y.
    Tuzuner, N.
    Ozbek, U.
    Soysal, T.
    HAEMATOLOGICA, 2014, 99 : 330 - 331
12345